Quote | Vaxcyte Inc. (NASDAQ:PCVX)
Last: | $75.45 |
---|---|
Change Percent: | 0.2% |
Open: | $71.49 |
Close: | $75.45 |
High: | $75.83 |
Low: | $71.1525 |
Volume: | 1,140,720 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
News | Vaxcyte Inc. (NASDAQ:PCVX)
2024-05-09 12:46:08 ET More on Vaxcyte Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript Vaxcyte, Inc. 2023 Q4 - Results - Earnings Call Presentation Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst Seeking Alpha’s Q...
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 In...
Message Board Posts | Vaxcyte Inc. (NASDAQ:PCVX)
Subject | By | Source | When |
---|---|---|---|
PCVX +16% on phase-2 data for VAX-24: | DewDiligence | investorshub | 04/17/2023 3:04:01 PM |
$PCVX gets BTD for VAX-24 in adult marketinvestors yawn: | DewDiligence | investorshub | 01/05/2023 3:17:24 PM |
$PCVX has around $1B(!) in cash: | DewDiligence | investorshub | 11/08/2022 12:05:41 AM |
Thank you DewDiligence! I'm happy for him. Larry | Phosphene | investorshub | 10/26/2022 10:32:52 PM |
It doesn't affect options already granted. It could | DewDiligence | investorshub | 10/26/2022 7:05:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Vaxcyte Inc. Company Name:
PCVX Stock Symbol:
NASDAQ Market:
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 In...
2024-04-23 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc (NASDAQ:PCVX) estimates it will grow...